ACP
THRD

Acuta Capital Partners’s Third Harmonic Bio THRD Stock Holding History

Acuta Capital Partners’s Portfolio THRD Stock Details THRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-49,800
Closed -$512K – 43
2024
Q4 		$512K Buy
49,800
+34,292
+221% +$427K 0.52% 33
2024
Q3 		$210K Buy
+15,508
New +$192K 0.17% 40

Other funds holding THRD

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Acuta Capital Partners's THRD Position: Q1 2025 in Review

Acuta Capital Partners sold out of Third Harmonic Bio (THRD) in Q1 2025, closing a stake of 49,800 shares — an estimated $512K sold.

Acuta Capital Partners first reported a position in THRD in Q3 2024 and held it in 2 quarters. The position peaked at $512K in Q4 2024. 99 funds tracked by Wall St. Rank hold THRD as of Q1 2025.

  • Acuta Capital Partners reported no remaining Third Harmonic Bio position as of Q1 2025 after selling out during the quarter.
  • Acuta Capital Partners sold 49,800 Third Harmonic Bio shares in Q1 2025, an estimated $512K.
  • Acuta Capital Partners first reported a position in Third Harmonic Bio in Q3 2024 and held it in 2 quarters.
  • Acuta Capital Partners's Third Harmonic Bio position peaked at $512K in Q4 2024.
  • 99 funds tracked by Wall St. Rank held Third Harmonic Bio as of Q1 2025.

Based on Acuta Capital Partners's 13F filing for Q1 2025, filed 15 May 2025.